Sanofi (SNW2) - Net Assets
Based on the latest financial reports, Sanofi (SNW2) has net assets worth €73.53 Billion EUR (≈ $85.97 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€129.79 Billion ≈ $151.74 Billion USD) and total liabilities (€56.26 Billion ≈ $65.78 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sanofi (SNW2) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €73.53 Billion |
| % of Total Assets | 56.65% |
| Annual Growth Rate | 3.81% |
| 5-Year Change | 23.29% |
| 10-Year Change | N/A |
| Growth Volatility | 3.21 |
Sanofi - Net Assets Trend (2016–2024)
This chart illustrates how Sanofi's net assets have evolved over time, based on quarterly financial data. Also explore how large is Sanofi's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Sanofi (2016–2024)
The table below shows the annual net assets of Sanofi from 2016 to 2024. For live valuation and market cap data, see Sanofi stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €77.86 Billion ≈ $91.02 Billion |
+4.71% |
| 2023-12-31 | €74.35 Billion ≈ $86.93 Billion |
+1.14% |
| 2022-12-31 | €73.51 Billion ≈ $85.94 Billion |
+6.49% |
| 2021-12-31 | €69.03 Billion ≈ $80.70 Billion |
+9.32% |
| 2020-12-31 | €63.15 Billion ≈ $73.83 Billion |
+6.83% |
| 2019-12-31 | €59.11 Billion ≈ $69.10 Billion |
+0.12% |
| 2018-12-31 | €59.03 Billion ≈ $69.02 Billion |
+1.33% |
| 2017-12-31 | €58.26 Billion ≈ $68.11 Billion |
+0.93% |
| 2016-12-31 | €57.72 Billion ≈ $67.49 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sanofi's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €77.51 Billion | 100.00% |
| Total Equity | €77.51 Billion | 100.00% |
Sanofi Competitors by Market Cap
The table below lists competitors of Sanofi ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank of Montreal
TO:BMO
|
$105.76 Billion |
|
Lockheed Martin Corporation
NYSE:LMT
|
$106.03 Billion |
|
State Bank of India
NSE:SBIN
|
$106.66 Billion |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
$107.56 Billion |
|
CME Group Inc
NASDAQ:CME
|
$105.05 Billion |
|
Cambricon Technologies Corp Ltd
SHG:688256
|
$104.90 Billion |
|
Medtronic plc
SA:MDTC34
|
$104.84 Billion |
|
Mizuho Financial Group Inc.
NYSE:MFG
|
$104.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sanofi's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 74,040,000,000 to 77,507,000,000, a change of 3,467,000,000 (4.7%).
- Net income of 5,560,000,000 contributed positively to equity growth.
- Dividend payments of 4,704,000,000 reduced retained earnings.
- Share repurchases of 302,000,000 reduced equity.
- New share issuances of 187,000,000 increased equity.
- Other factors increased equity by 2,726,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €5.56 Billion | +7.17% |
| Dividends Paid | €4.70 Billion | -6.07% |
| Share Repurchases | €302.00 Million | -0.39% |
| Share Issuances | €187.00 Million | +0.24% |
| Other Changes | €2.73 Billion | +3.52% |
| Total Change | €- | 4.68% |
Book Value vs Market Value Analysis
This analysis compares Sanofi's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.85x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €46.32 | €39.40 | x |
| 2018-12-31 | €47.27 | €39.40 | x |
| 2019-12-31 | €47.00 | €39.40 | x |
| 2020-12-31 | €50.37 | €39.40 | x |
| 2021-12-31 | €54.83 | €39.40 | x |
| 2022-12-31 | €58.01 | €39.40 | x |
| 2023-12-31 | €59.17 | €39.40 | x |
| 2024-12-31 | €61.83 | €39.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sanofi utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.17%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.55%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.71x
- Recent ROE (7.17%) is below the historical average (9.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 8.18% | 13.57% | 0.33x | 1.82x | €-1.05 Billion |
| 2017 | 14.52% | 23.30% | 0.36x | 1.72x | €2.63 Billion |
| 2018 | 7.31% | 12.07% | 0.32x | 1.89x | €-1.58 Billion |
| 2019 | 4.76% | 7.46% | 0.33x | 1.91x | €-3.09 Billion |
| 2020 | 19.55% | 32.95% | 0.33x | 1.82x | €6.01 Billion |
| 2021 | 9.06% | 15.89% | 0.33x | 1.75x | €-645.10 Million |
| 2022 | 9.19% | 14.81% | 0.36x | 1.70x | €-594.40 Million |
| 2023 | 7.29% | 12.98% | 0.33x | 1.71x | €-2.00 Billion |
| 2024 | 7.17% | 12.55% | 0.33x | 1.71x | €-2.19 Billion |
Industry Comparison
This section compares Sanofi's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $20,263,098,473
- Average return on equity (ROE) among peers: 9.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sanofi (SNW2) | €73.53 Billion | 8.18% | 0.77x | $105.72 Billion |
| Bayer AG NA (BAYN) | $33.17 Billion | 3.01% | 2.63x | $43.70 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $489.18 Million | -0.74% | 0.25x | $1.65 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $9.13 Billion | 20.61% | 0.45x | $10.18 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $35.02 Billion | 16.77% | 0.32x | $11.04 Billion |
| Grifols S.A (G0FB) | $6.72 Billion | 10.55% | 1.27x | $1.99 Billion |
| AstraZeneca PLC (ZEGA) | $37.06 Billion | 8.87% | 1.60x | $252.57 Billion |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting aga… Read more